July 2nd 2025
Research from the Karolinska Institute reveals that therapies such as dupilumab and mepolizumab may not eliminate Th2 lymphocytes, raising concerns about long-term remission.
Tumor Board: Expert Insights on Managing Classical šššš Mutations, šššš Exon 20 Insertions, and Atypical šššš Mutations in Metastatic NSCLC
View More
Medical CrossfireĀ®: Expert Perspectives on Targeting c-Met Overexpression and ššš Genomic Alterations in NSCLC ā Unveiling the Complexities of ššš Dysregulation
View More
PER Tumor BoardĀ®: Applying Recent Advances to Transform the Treatment Paradigm in SCLCāExpert Perspectives on New Approvals and Emerging Strategies
View More
Medical CrossfireĀ®: The Precision Path for HER2 and TROP2-Targeted Treatments in NonāSmall Cell Lung Cancer
View More
Medical CrossfireĀ®: DLL3-Driven Innovations in Small Cell Lung Cancer ā How Do Experts Apply Pivotal Advances to Practice?
View More
Top 10 Oncogenic Drivers in NSCLC for 2024: Where Are We and Where Are We Going?
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
DLL3 as a Therapeutic Target in SCLC and Beyond: Rationale, Recent Data and Potential for Transformations in Care with T-Cell Engagers
View More
Lung Cancer Tumor BoardĀ®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
26th Annual International Lung Cancer CongressĀ®
July 25-26, 2025
Register Now!
Surv.AI Says: Real-World Insights Into the Journey for Patients With Pulmonary Arterial Hypertension
View More
Advances Inā¢: Moving Care Forward in SCLC with DLL3 Targeting Bispecific T-Cell Engagers
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Whatās Next for HER2- and TROP2-Directed ADCs in Lung Cancer: How Emerging Trial Data will Impact our Clinics Today, and Tomorrowā¦.
View More
Do We Have Sea Change in Small Cell Lung Cancer? What Recent Clinical Trial Data Tell Us About Treatment Decision-Making in Real-World Settings, Whatās Next for Emerging Novel Strategies
View More
Community Practice Connectionsā¢: 25th Annual International Lung Cancer Congress
View More
Community Practice Connectionsā¢: 8th Annual School of Nursing Oncologyā¢
View More
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) Lung Cancer Tumor BoardĀ®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(MOC and CME Credit) Lung Cancer Tumor BoardĀ®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
20th Annual New York Lung Cancers SymposiumĀ®
November 15, 2025
Register Now!
Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management
View More
Cases & Conversationsā¢: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC ā Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies
View More
Burst CMEā¢: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L
View More
Burst CMEā¢: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC
View More
Burst CMEā¢: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC
View More
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!